国产亚洲欧美日韩俺去了,人妻无码久久精品,亚洲人成影院在线观看,亚洲AV永久无码精品表情包

英國Pro-Cure Therapeutics Limited (Pro-Cure)
從大學(xué)的癌癥研究所內部發(fā)展出來(lái)的一家企業(yè)，從事前列腺癌基因療法的研究。

Pro-Cure Therapeutics Limited (Pro-Cure) is a UK-based R&D company that is focused on cancer stem cell therapies - with an initial interest in prostate cancer stem cells.

Founded on the work of Professor Norman Maitland and Dr Anne Collins of the Yorkshire Cancer Research (YCR) Cancer Research Unit (CRU) at York University, the Company has identified drug targets for new classes of cancer drugs that fundamentally change the management of prostate cancer by preventing cancer stem cells' ability to initiate new tumours, to prevent recurrence, prevent metastasis and as an effective treatment for drug-resistant forms of prostate cancer.

Pro-Cure seeks alliances with companies to develop new therapeutics against these exciting new targets. Pro-Cure is pursuing MAb approaches to selected targets but targets are also identified that are suited to other therapeutic technologies such as small molecules (different classes of receptors and targets have been identified including common drug targets such as kinases, proteases, etc.), siRNA and peptides. We also have other targets in validation that are suited to antibody therapies and vaccines.